Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy
2016-004263-38Phase 2Completed
- Sponsor
- ReveraGen BioPharma
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vamorolone in Duchenne muscular dystrophy (DMD), sponsored by ReveraGen BioPharma. Started Dec 2016; status: completed.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2016-004263-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004263-38.